Stoke Therapeutics Plans to Initiate a Phase 3 Study of Zorevunersen

“I have participated as an investigator in many clinical research studies, nearly all of which have been designed to test the next best anti-seizure medicine,” said Kelly Knupp, MD, MSCS, Professor of Pediatrics and Neurology at the University of Colorado Anshutz Medical Campus and the Dravet Program Director and Epilepsy Program Lead at Children's Hospital Colorado. “What families and we as clinicians now want are medicines that go beyond reducing seizures to address the neurodevelopmental issues associated with Dravet syndrome, including giving patients the ability to communicate with the people around them and achieve a certain level of independence, which cannot be achieved with today’s standard of care. This is the first Phase 3 study to assess the effects of a disease-modifying medicine on seizures as well as multiple aspects of cognition and behavior, which could lead us into a new era in the treatment of Dravet syndrome.”